Todos Medical, Ltd. together with its 3CL biology-focused joint venture partner NLC Pharma, announced that all 31 patients enrolled to date in Tollovir® Phase II clinical trial in hospitalized COVID-19 patients completed study participation.
[Todos Medical, Ltd.]
6445212
CCCCCCCC
items
1
apa
0
default
asc
1
169664
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
